{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:09:27Z","timestamp":1792343367166,"version":"4.4.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>\n                      Severe transfusion reactions to group B\u2013incompatible platelets and plasma possibly related to the \u03b1\u2010gal syndrome (\n                      <jats:styled-content style=\"fixed-case\">AGS<\/jats:styled-content>\n                      ) have been recently described.\n                      <jats:styled-content style=\"fixed-case\">AGS<\/jats:styled-content>\n                      is a potentially severe Immunoglobulin E mediated allergy to mammalian meat and meat\u2010derived products associated with tick bites. The involved allergen, galactose\u2010\u03b1\u20101,3\u2010galactose (\u03b1\u2010gal), is antigenically similar to the blood group B antigen. To further assess a potential association between\n                      <jats:styled-content style=\"fixed-case\">AGS<\/jats:styled-content>\n                      and allergic transfusion reactions (ATRs), we comparatively assessed the frequency of ATRs after plasma or platelet concentrate (PC) transfusion in relation to the degree of ABO compatibility between the recipient and the involved blood component in France.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In France, all transfusions are centrally recorded, and ATR reporting is mandatory. Frequencies of severe ATRs involving PC or plasma in relation to ABO group distributions were analysed between 1 January 2022 and 31 December 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 981,955 PC and 580,230 plasma evaluable transfusions, severe ATRs were significantly higher in group O recipients transfused with group B or AB platelets (relative risk [RR]: 5.06, 95% confidence interval [CI]: 3.27\u20137.83,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and plasma (RR: 2.15, 95% CI: 1.37\u20133.36,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) while not in group A recipients of group B or AB platelets (RR: 0.95, 95% CI: 0.30\u20132.96) or plasma (RR: 0.92, 95% CI: 0.45\u20131.88), when compared to ATR rates in all other recipients of PC or plasma, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this national retrospective haemovigilance analysis, group B or\n                      <jats:styled-content style=\"fixed-case\">AB PC<\/jats:styled-content>\n                      or plasma transfused to group O recipients is associated with an increased risk of severe\n                      <jats:styled-content style=\"fixed-case\">ATRs<\/jats:styled-content>\n                      . Further studies will establish whether\n                      <jats:styled-content style=\"fixed-case\">AGS<\/jats:styled-content>\n                      is involved in this increased risk.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vox.70136","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:14:36Z","timestamp":1761786876000},"page":"81-86","source":"Crossref","is-referenced-by-count":8,"title":["Association between group B major\n                    <scp>ABO<\/scp>\n                    \u2010incompatible platelet or plasma transfusion and severe allergic reactions: A nationwide haemovigilance analysis suggesting a role for \u03b1\u2010gal syndrome. A Biomedical Excellence for Safer Transfusion Collaborative study"],"prefix":"10.1111","volume":"121","author":[{"given":"Lucile","family":"Malard","sequence":"first","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang  La Plaine Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9o","family":"Beuscart","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang  La Plaine Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"de Chaisemartin","sequence":"additional","affiliation":[{"name":"Service d'Immunologie Biologique CHU Bichat, AP\u2010HP  Paris France"},{"name":"UMR 1149, Universit\u00e9 Paris Cit\u00e9, INSERM, Centre de Recherche sur l'Inflammation, Equipe InnaLung  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"de la Taille","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang  La Plaine Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Delettre","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang  Besan\u00e7on France"},{"name":"UMR RIGHT 1098, Universit\u00e9 Marie et Louis Pasteur, INSERM, Etablissement Fran\u00e7ais du Sang  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Humbrecht","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Dunbar","sequence":"additional","affiliation":[{"name":"Dartmouth\u2010Hitchcock Medical Center  Lebanon New Hampshire USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-3580","authenticated-orcid":false,"given":"Sophie","family":"Lecam","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang  La Plaine Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-0108","authenticated-orcid":false,"given":"Syria","family":"Laperche","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang  La Plaine Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9310-8322","authenticated-orcid":false,"given":"Pierre","family":"Tiberghien","sequence":"additional","affiliation":[{"name":"\u00c9tablissement Fran\u00e7ais du Sang  La Plaine Saint\u2010Denis France"},{"name":"UMR RIGHT 1098, Universit\u00e9 Marie et Louis Pasteur, INSERM, Etablissement Fran\u00e7ais du Sang  Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Biomedical Excellence for Safer Transfusion (BEST) Collaborative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Practical transfusion medicine","author":"Harm SK","year":"2022"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15845"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17161"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335911"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70035"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.10.018"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ttbdis.2019.05.017"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70130"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.165.3.693"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055566"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13400"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.18405"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17521"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17811"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.07.050"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.03.031"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01210"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.18338"},{"key":"e_1_2_9_20_1","unstructured":"e\u2010FIT National Hemovigilance Database ANSM. Available from:https:\/\/ansm.sante.fr\/uploads\/2021\/01\/28\/guide-d-utilisation-de-l-application-e-fit-feir-12062013.pdf[in French]. Last accessed 29 Jun 2025."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15655"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7230a2"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.164"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10719-005-0508-x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13697"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15275"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12597"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00865-22"},{"key":"e_1_2_9_29_1","unstructured":"ANSM hemovigilance report.2023. Available from:rapport-hv-2023-summary-en.pdf. Last accessed 29 Jul 2025."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2018.12.021"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.70136","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.70136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:07:36Z","timestamp":1768435656000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.70136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/vox.70136"],"URL":"https:\/\/doi.org\/10.1111\/vox.70136","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}